Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ToxiBan is a veterinary gastrointestinal decontaminant used to treat acute poisoning and toxin ingestion in animals. It is a combination formulation containing activated charcoal and kaolin. Activated charcoal (specifically the MedChar brand used by the developer) acts as a highly effective, non-specific adsorbent with a large surface area that binds to a wide range of toxins, chemicals, and drugs within the digestive tract, thereby preventing their absorption into the systemic circulation. Kaolin serves as a secondary adsorbent and provides a protective coating to the intestinal mucosa. ToxiBan is available in several forms, including a suspension and granules, and is commonly used in dogs, cats, and livestock. Some specific versions, such as ToxiBan Suspension with Sorbitol, also include sorbitol to act as a cathartic, facilitating the rapid transit and fecal excretion of the charcoal-toxin complex.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on activated charcoal + kaolin.